UBS Wan Chau to join the key buy list target price of 8.61 yuan-tamiflu

UBS: Wanzhou to focus on buying list the target price of 8.61 yuan a thousand thousand shares hot column capital flows on stock diagnosis the latest rating simulated trading client sina finance App: Live on-line blogger to tutor Sina Hong Kong APP: real time market exclusive reference stocks also worth the investment? What’s the problem? Where is the future? Sina Hong Kong stocks launched "Hong Kong stocks are not attractive" big discussion, with a rational and constructive attitude, welcome to pay attention to Hong Kong stocks, people concerned about the capital market, together with Hong Kong stocks for advice and suggestions, and conspiracy of Hong Kong stock market tomorrow. Please to hkstock_biz@sina. UBS issued a research report, the Wanzhou International (00288.HK) this year the stock outperformed the Hang Seng Index of 35%, while 2014 to 2016 recorded 29% earnings growth, but the stock market is still close to August 2014 only. UBS added Wanzhou into the key buy list, raising the target price from 7.99 yuan to 8.61 yuan. Equivalent to 15 times forecast earnings in 2017, or 8 times EV EBITDA forecast in 2017. UBS said that China’s subsidiary Shuanghui and the United States Smithfield synergies, as well as the U.S. downstream business margin improvement, as well as the balance sheet tends to health, are favorable factors. UBS announced that Wanzhou announced in August 25th that the private equity fund CDH placed 1 billion 555 million shares, priced at 5.95 yuan per share, compared with the previous day closing price of 5% discount. Wanzhou management bought 292 million shares, the shareholding increased to 36.01%, while CDH decreased to 19.77%. UBS believes that this reflects the management’s confidence in the company’s prospects. UBS expects the CDH in the next two years and continued selling shares, Wanzhou Management Holdings of shares, and will increase the dividend through financing means, the 30% payout ratio rising. UBS upgraded the earnings forecasts of Wanzhou island from 2016 to 2018 by 7%, 5% and 6%, reflecting the cost control of Shuanghui and Smithfield, as well as the expected rapid growth of Smithfield packaged meat in the mainland, easing the decline in sales of old products. Due to the strong cash productivity of Wanzhou, UBS raised the dividend payout ratio forecast for Wanzhou in 2017 and beyond, and increased from 30% to 50%. (both) go into Sina Finance shares

瑞银:将万洲加入重点买入名单 目标价8.61元 热点栏目 资金流向 千股千评 个股诊断 最新评级 模拟交易 客户端 新浪财经App:直播上线 博主一对一指导 新浪港股APP:实时行情 独家内参   港股还值不值得投资?出现了什么问题?未来出路在哪里?新浪港股发起“港股还有没有吸引力”大讨论,以理性、建设性的态度,欢迎关注港股、关注资本市场的人士,一起为港股建言献策,共谋港股市场的明天。来稿请至hkstock_biz@sina 。   瑞银发表研究报告,指万洲国际(00288.HK)今年股价表现跑赢恒指35%,虽然2014年至2016年录29%盈利增长,但股价仅仍接近2014年8月上市价。瑞银把万洲加入重点买入名单,目标价由7.99元提升至8.61元。相当於2017年预测市盈率15倍,或2017年预测EV EBITDA的8倍。瑞银称,万洲的中国附属双汇及美国Smithfield具协同效应,以及美国下游业务毛利改善,以及资产负债表趋向健康,均是有利因素。   瑞银称,万洲在8月25日宣布,私募基金CDH配售15.55亿股,每股作价5.95元,较对上一日收市价折让5%。万洲管理层购入2.92亿股,持股量增至36.01%,CDH则减至19.77%。   瑞银认为,这反映管理层对公司前景有信心。瑞银料CDH在未来两年续沽售股份,而万洲管理层会增持股份,并会透过增加派息作融资,意味现时30%的派息比率有上升空间。瑞银提升万洲2016年至2018年盈利预测7%、5%及6%,以反映双汇及Smithfield的成本控制,及Smithfield包装肉在内地较预期快的增长,纾缓了旧产品销量下滑。由於万洲现金生产力强,瑞银提升万洲2017年及以後的派息比率预测,料由30%增至50%。(双双) 进入【新浪财经股吧】讨论相关的主题文章: